[The treatment of metastasizing breast carcinoma using antiestrogens]

Results of adjuvant hormone therapy with Tamoxifen, an antioestrogenic substance, have been discussed. 82 patients in 2 groups who were diagnosed with metastatic mammary carcinoma received Tamoxifen (ICI) and Tamoxifen (Ebewe) orally in a dosage of 20 to 40 mg/day. 43% of the patients in group A (Tamoxifen, ICI) experienced complete or partial remission of the metastases. In group B (Tamoxifen, Ebewe), this result was achieved in 54% of cases. The better results were due to the fact that the disease was not so advanced in the group B patients and they were also longer in the menopause. Thus in terms of efficacy, the preparations are identical. Severe side effects due to the therapy were not observed.